Home » Natco Pharma Files First ANDA for Generic Version of Tamiflu
Natco Pharma Files First ANDA for Generic Version of Tamiflu
Indian drugmaker Natco Pharma has filed an ANDA for a generic version of Tamiflu, challenging Gilead’s patent protection on the drug. The application, which was revealed by Natco on Feb. 9, is believed to be the first for a generic version of the blockbuster anti-viral and would entitle the company to 180 days of marketing exclusivity, Natco says. Tamiflu (oseltamivir phosphate) is approved for the treatment of adults and children 1 year and older with influenza whose symptoms started within two days. The drug, which is sold by Genentech, had more than $911 million in 2010 sales and has been used as a treatment for bird and swine flu infections.
Generic Line
Generic Line
Upcoming Events
-
07May
-
14May
-
30May